Business | Wednesday February 13, 2013
Slower government approval for testing new medicines is threatening India's aspirations to be a fast-growing, low-cost hub for clinical trials, and has prompted some drug firms to shift operations elsewhere, adding to their costs.
www.ndtv.com/business